Iambic Therapeutics Files for Nasdaq IPO to Fund Three Cancer Candidates
核心洞察
Iambic Therapeutics (搜索) filed an S-1 with the SEC on September 21, 2026 to list on the Nasdaq Global Select Market under the ticker IAM.
Proceeds will advance clinical development of lead HER2 (搜索) inhibitor IAM1363 plus preclinical candidates IAM217 (搜索) and IAM-C1, alongside general corporate purposes.
IAM1363, an oral pan-mutant brain-penetrant HER2 (搜索) inhibitor, is in a Phase 1/1b basket study with a registrational trial planned as early as 2027.
Iambic Therapeutics (搜索), Inc. filed a registration statement with the U.S. Securities and Exchange Commission on September 21, 2026 for an initial public offering on the Nasdaq Global Select Market under the ticker "IAM." The filing did not disclose the number of shares to be offered or an expected price range. J.P. Morgan, Jefferies, BofA Securities and Citigroup are underwriting the offering.
The company said it plans to use IPO proceeds, together with existing cash, to continue advancing its three cancer drug candidates through clinical development, with remaining funds directed to working capital and general corporate purposes.
Lead Program in Phase 1/1b
Iambic's lead candidate, IAM1363, is an oral, highly selective, pan-mutant, brain-penetrant HER2 (搜索) inhibitor. It is being evaluated in an ongoing Phase 1/1b basket study, with plans to initiate a registrational trial as early as 2027, subject to regulatory feedback. The program targets tumors driven by the HER2 protein.
Two additional candidates are in preclinical development, with planned IND submissions in the fourth quarter of 2026. IAM217 (搜索) is a brain-penetrant, allosteric KIF18A (搜索) inhibitor, and IAM-C1 is a selective dual CDK2 (搜索)/4 inhibitor. Iambic said it intends to seek FDA clearance to begin human trials on both by the end of the year.
Platform and Partnerships
Founded in 2019, Iambic describes its approach as "molecular superintelligence," combining proprietary large-scale AI with automated chemistry and biology to design and advance small-molecule drugs. The platform integrates Enchant, a multimodal transformer model that predicts preclinical and clinical properties, with NeuralPLexer, a generative structure engine for protein-ligand complexes, and a closed-loop automated lab for rapid design-make-test cycles.
The company partners with pharmaceutical and technology firms including AbbVie, Takeda, Lundbeck, NVIDIA (搜索), Lambda, Revolution Medicines, Jazz Pharmaceuticals and Bayer (搜索) to deploy its platform across additional targets and indications. Iambic reported $12.8 million in collaboration revenue for the six months ended June 30, 2026. Full-year 2025 collaboration revenue was $9.4 million, up from $1.2 million in 2024. The company recorded a loss from operations of $53.5 million and a net loss of $50.1 million for the six months ended June 30, 2026, and a net loss of $77.3 million for full-year 2025, compared with $47.9 million in 2024.
Iambic has raised approximately $461.8 million in capital since its founding through September 18, 2026. Its five largest shareholders are Catalio, Nexus Ventures, Q Healthcare Holding, Nvidia (搜索) and Coatue Ventures. The company is headquartered in San Diego, California, with additional offices in Bristol, UK and Dublin, Ireland, and reported 171 full-time employees as of September 18, 2026. Clinical operations are based in the U.S. and EU, with planned UK and APAC site expansions.
Competitive Landscape
Iambic lists Recursion, Relay Therapeutics, Generate Biomedicines (搜索), Insilico Medicine (搜索), Isomorphic Labs (搜索), Xaira (搜索), AbCellera, Absci and XtalPi (搜索) among its competitors. The company estimates multi-billion-dollar opportunities across HER2-driven cancers (搜索) and other indications, including more than $10 billion for IAM1363 and IAM-C1, more than $5 billion for IAM217 (搜索), and approximately $70 billion across discovery-stage programs. It cites rapid advances in frontier AI, expansion of high-throughput experimentation, growing pharma partnerships and increasing focus on CNS-active and mutant-selective targeted therapies as industry trends shaping its strategy.